Skip to main content

Company

Emyria Ltd

ASX:EMD

Emyria Limited develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and treatment development.

29 stories

Small Cap Watch: Lindian advances Kangankunde, Titan hits high-grade gold-silver and Emyria removes bottlenecks

By Jonathan Jackson 20/08

Pharma & Biotech

Emyria on track for first Victorian Empax clinic launch in Q2 2026

By Proactive 24/03

Pharma & Biotech

Emyria delivers more than $2 million in clinical billings in the past half-year

By Proactive 29/02/2024

Pharma & Biotech

Emyria kicks off year with $2.5 million R&D incentive on the heels of Authorised Prescriber status

By Proactive 15/01/2024

Pharma & Biotech

Emyria gains authorised provider status for MDMA from TGA for post-traumatic stress disorder

By Proactive 10/01/2024

Pharma & Biotech

Emyria welcomes eminent healthcare leader to enhance mental health initiatives

By Proactive 21/11/2023

Pharma & Biotech

Emyria restructures board amid cost efficiency commitment

By Proactive 13/11/2023

Pharma & Biotech

Emyria secures ethics endorsement for MDMA Authorised Prescriber application, clearing way for TGA decision

By Proactive 30/10/2023

Pharma & Biotech

Emyria given green light to import MDMA for therapeutic trials in Australia

By Proactive 19/10/2023

Pharma & Biotech

Emyria completes first approved MDMA-assisted therapy dosing

By Proactive 09/10/2023

Pharma & Biotech

Emyria completes entitlement offer, raises $1.18m ahead of MDMA-assisted therapy trial

By Proactive 05/10/2023

Pharma & Biotech

Emyria secures local MDMA paving way for PTSD trial dosing

By Proactive 21/09/2023

Pharma & Biotech

Emyria completes Pax Centre acquisition to boost mental health care and drug development

By Proactive 13/09/2023

Pharma & Biotech

Emyria raises $2 million in placement; launches $3.1 million entitlement offer

By Proactive 04/09/2023

Pharma & Biotech

Emyria appoints clinical transformation and digital health expert to board

By Proactive 21/08/2023

Pharma & Biotech

Emyria launches ketamine-assisted therapy program; taps expert Dr Ben Sessa to lead

By Proactive 08/08/2023

Pharma & Biotech

Emyria recruits first patient in Phase 2B trial of MDMA for post-traumatic stress disorder

By Proactive 10/07/2023

Pharma & Biotech

Emyria pursues a unique opportunity in psychedelic-assisted therapy

By Proactive 06/07/2023

Pharma & Biotech

Emyria set to snap up leading psychological trauma care service, the Pax Centre

By Proactive 03/07/2023

Pharma & Biotech

Cannabis and psychedelic regulation in Australia

By Proactive 27/06/2023

Pharma & Biotech

The smart money in medicine: cannabis and psychedelics come of age

By Proactive 13/06/2023

Pharma & Biotech

Emyria gains ethics approval for landmark MDMA-assisted PTSD therapy trial

By Proactive 08/06/2023

Pharma & Biotech

Emyria completes $2.5M placement to advance MDMA-assisted therapy

By Proactive 01/05/2023

Pharma & Biotech

Emyria expands CBD pipeline with launch of highest potency Ultra-Pure CBD capsule

By Proactive 24/04/2023

Pharma & Biotech

Emyria extends PAX partnership to develop psilocybin-assisted therapy care model

By Proactive 18/04/2023

Pharma & Biotech

Emyria and pharma company Aspen Australia ink agreement to license and commercialise EMD-RX5 as OTC anxiety medication

By Proactive 04/04/2023

Pharma & Biotech

Emyria experiences high patient demand as it enrols for Phase 3 trial of OTC treatment for stress and anxiety

By Proactive 23/03/2023

Pharma & Biotech

Emyria and UWA expand MDMA analogue library to target neurological and mental health conditions

By Proactive 20/03/2023

Pharma & Biotech

Emyria collaborates with psychiatrist-led clinical service in MDMA-assisted therapy for PTSD

By Proactive 07/03/2023